Fosun Pharma Unit's Registration Application for Langerhans Cell Histiocytosis Drug Accepted in China

MT Newswires Live

2025/11/21

Shanghai Fosun Pharmaceutical's (SHA:600196, HKG:2196) said unit Shanghai Fosun Pharmaceutical Industrial Development's drug registration application for Luvometinib Tablets was accepted by China's National Medical Products Administration, a Friday Hong Kong bourse filing said.

The drug is indicated for the treatment of pediatric patients aged 2 years and older with Langerhans cell histiocytosis (LCH).

The application was included in the list of priority review.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2585114294"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2585114294\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2585114294?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-21 18:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2585114294","market":"sg","top_or_hot":-1,"title":"Fosun Pharma Unit's Registration Application for Langerhans Cell Histiocytosis Drug Accepted in China","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/SFOSF\">Shanghai Fosun</a> Pharmaceutical's (SHA:600196, HKG:2196) said unit <a href=\"https://laohu8.com/S/600196\">Shanghai Fosun</a> Pharmaceutical Industrial Development's drug registration application for Luvometinib Tablets was accepted by China's National Medical Products Administration, a Friday Hong Kong bourse filing said.</p><p>The drug is indicated for the treatment of pediatric patients aged 2 years and older with Langerhans cell histiocytosis (LCH).</p><p>The application was included in the list of priority review.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Fosun Pharma Unit's Registration Application for Langerhans Cell Histiocytosis Drug Accepted in China</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFosun Pharma Unit's Registration Application for Langerhans Cell Histiocytosis Drug Accepted in China\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2025-11-21 18:54</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/SFOSF\">Shanghai Fosun</a> Pharmaceutical's (SHA:600196, HKG:2196) said unit <a href=\"https://laohu8.com/S/600196\">Shanghai Fosun</a> Pharmaceutical Industrial Development's drug registration application for Luvometinib Tablets was accepted by China's National Medical Products Administration, a Friday Hong Kong bourse filing said.</p><p>The drug is indicated for the treatment of pediatric patients aged 2 years and older with Langerhans cell histiocytosis (LCH).</p><p>The application was included in the list of priority review.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0183","symbol_name":"MSCI概念","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2585114294","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2585114294","pubTimestamp":1763722440,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Shanghai Fosun Pharmaceutical's  said unit Shanghai Fosun Pharmaceutical Industrial Development's drug registration application for Luvometinib Tablets was accepted by China's National Medical Products Administration, a Friday Hong Kong bourse filing said.The drug is indicated for the treatment of pediatric patients aged 2 years and older with Langerhans cell histiocytosis .The application was included in the list of priority review.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600196":"复星医药","BK0183":"MSCI概念","00656":"复星国际","BK1191":"制药","BK1515":"抗疫概念","BK0096":"民营医院","BK0188":"融资融券","BK0012":"证金概念","BK1593":"医美概念股","02196":"复星医药","BK0175":"白马股","BK0196":"行业龙头","BK0060":"抗癌","BK0187":"一线龙头","BK1230":"工业集团企业","BK0028":"国家队","BK0239":"医药制造"},"translate_title":"复星医药单位朗格汉斯细胞组织细胞增生症药物注册申请在中国获受理","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600196":0.9,"02196":0.9,"00656":1.5},"content_text":"Shanghai Fosun Pharmaceutical's (SHA:600196, HKG:2196) said unit Shanghai Fosun Pharmaceutical Industrial Development's drug registration application for Luvometinib Tablets was accepted by China's National Medical Products Administration, a Friday Hong Kong bourse filing said.The drug is indicated for the treatment of pediatric patients aged 2 years and older with Langerhans cell histiocytosis (LCH).The application was included in the list of priority review.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}